May 6, 2009
Inspire Pharmaceuticals Inc. announced it has initiated two phase II clinical trials with azithromycin ophthalmic solution 1% (AzaSite) to pursue a potential indication for the treatment of blepharitis. The drug currently is approved by the FDA for the treatment of bacterial conjunctivitis.
 |
May 6, 2009
Novagali Pharma announced that the company's investigational new drug application to conduct a phase III clinical trial of Nova21027 (Catioprost), a cationic emulsion of latanoprost for the treatment of glaucoma, has been granted by the FDA.
|
May 6, 2009
Second Sight Medical Products Inc. announced that the FDA has granted approval for up to 20 people who are blind or who have severely impaired vision due to retinitis pigmentosa to participate in a feasibility study for its retinal implant (Argus II Retinal Implant) in the United States. Ten RP volunteers are participating in the U.S. study and an additional 12 RP volunteers are participating in similar studies throughout Europe and Mexico.
|
July 1, 2007
By:Stephanie Davis
The Wilmer Eye Institute of Johns Hopkins University School of Med-icine opened a $100 million, privately funded, 207,000-square-foot facility that will build on the current research and clinical space for its 130 full-time faculty (90 clinician scientists; 40 PhD researchers).
|
June 15, 2007
Lincoln, RI?Biotechnology firm Neurotech Pharmaceuticals Inc. has begun two phase II/III clinical trials with NT-501, the company's lead Encapsulated Cell Technology (ECT) product for the treatment of visual loss associated with retinitis pigmentosa.
|
June 15, 2007
San Diego?Advanced Medical Optics (AMO) Inc. has introduced a new phacoemulsification system featuring dual-pump fluidics (WhiteStar Signature with Fusion).
|
June 15, 2007
Tampa, FL?Two companies are researching cyclosporine A as a potential treatment for dry eye syndrome.
|
June 15, 2007
Irvine, CA?Medennium Inc. expects that its photochromic IOL (Aurium) will be available in all European countries by September now that it has obtained CE mark clearance to market the lens. It is the first and only photochromic IOL, according to the company.
|
June 15, 2007
Bethesda, MD?The FDA will allow Regene-Rx Biopharmaceuticals Inc. to begin a phase II trial of its Thymosin beta 4 (TB4) for the treatment of diabetic patients undergoing vitrectomy surgery.
|
| 
Practice Tools
